MENU
+Compare
NONOF
Stock ticker: OTC
AS OF
Sep 17 closing price
Price
$57.63
Change
+$0.16 (+0.28%)
Capitalization
251.44B

NONOF stock forecast, quote, news & analysis

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world... Show more

NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for NONOF with price predictions
Sep 17, 2025

NONOF in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 10, 2025

NONOF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 30 cases where NONOF's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 16, 2025. You may want to consider a long position or call options on NONOF as a result. In of 113 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NONOF just turned positive on August 14, 2025. Looking at past instances where NONOF's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

NONOF moved above its 50-day moving average on September 17, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NONOF advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NONOF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.671) is normal, around the industry mean (9.454). P/E Ratio (14.658) is within average values for comparable stocks, (23.720). Projected Growth (PEG Ratio) (1.439) is also within normal values, averaging (1.758). Dividend Yield (0.030) settles around the average of (0.028) among similar stocks. P/S Ratio (5.222) is also within normal values, averaging (3.441).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NONOF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NONOF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

NONOF paid dividends on August 18, 2021

Novo-Nordisk A/S NONOF Stock Dividends
А dividend of $7.00 per share was paid with a record date of August 18, 2021, and an ex-dividend date of August 16, 2021. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 88.9B. The market cap for tickers in the group ranges from 72.83K to 685.53B. LLY holds the highest valuation in this group at 685.53B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 11%. MDCX experienced the highest price growth at 20%, while JCRRF experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 22%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -77%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 69
Price Growth Rating: 54
SMR Rating: 61
Profit Risk Rating: 80
Seasonality Score: -36 (-100 ... +100)
View a ticker or compare two or three
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Novo Alle 1
Phone
+45 44448888
Employees
64319
Web
https://www.novonordisk.com